Key result
Metformin has great potential to mitigate the adverse effects of radiation exposure by activating cellular antioxidant and repair systems to eliminate the harmful consequences of disrupted redox homeostasis.
Why the study?
Does metformin mitigate the adverse effects of radiation exposure in patients exposed to ionizing radiation?
Does metformin mitigate the adverse effects of radiation exposure in patients exposed to ionizing radiation?
Metformin shows potential as a radioprotective agent by countering oxidative stress and mitigating the adverse effects of ionizing radiation.
May support metformin investigation for radiation-exposed patients; leaves open clinical efficacy pending randomized trials.
Metformin (1,1-dimethylbiguanidine hydrochloride) (MF) is a drug that has long been in use for the treatment of type 2 diabetes mellitus and recently is coming into use in the radiation therapy of cancer and other conditions. Exposure to ionizing radiation disturbs the redox homeostasis of cells and causes damage to proteins, membranes, and mitochondria, destroying a number of biological processes. After irradiation, MF activates cellular antioxidant and repair systems by signaling to eliminate the harmful consequences of disruption of redox homeostasis. The use of MF in the treatment of the negative effects of irradiation has great potential in medical patients after radiotherapy and in victims of nuclear accidents or radiologic terrorism.
No takes yet. Share an insight, caveat, or question.
Karmanova et al. (2023) conducted a review in Radiation exposure. Metformin was evaluated. Metformin has great potential to mitigate the adverse effects of radiation exposure by activating cellular antioxidant and repair systems to eliminate the harmful consequences of disrupted redox homeostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: